LibyaTuberculosis profile
Population  2014 6.3 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.61 (0.43–0.82) 9.7 (6.8–13)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 4.5 (2.3–7.5) 73 (37–120)
Incidence  (includes HIV+TB) 2.5 (2.1–3) 40 (33–48)
Incidence (HIV+TB only) 0.1 (0.08–0.12) 1.6 (1.3–2)
         
Case detection, all forms (%) 46 (39–56)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 3.2 (2.3–4.1) 17 (11–23)
MDR-TB cases among notified pulmonary
TB cases
24 (17–31) 7 (5–10)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 526   11
Pulmonary, clinically diagnosed 232   0
Extrapulmonary 384   0
       
Total new and relapse 1 153    
Previously treated, excluding relapses 32    
Total cases notified 1 185    
Among 1 153 new and relapse cases:
69 (6%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 0 (0%) 0
Laboratory-confirmed RR-/MDR-TB cases      
Patients started on MDR-TB treatment ***     0
TB/HIV 2014 Number (%)
TB patients with known HIV status 1 142 (96)
HIV-positive TB patients 54 (5)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (59) 1 345
Previously treated cases, excluding relapse, registered in 2013 (20) 71
HIV-positive TB cases, all types, registered in 2013 (27) 52
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 16.0
Drug susceptibility testing (per 5 million population) 1.6
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-02 Data: www.who.int/tb/data